Gyre Therapeutics (NASDAQ:GYRE) Trading Down 4.4% After Insider Selling

Gyre Therapeutics, Inc. (NASDAQ:GYRE) traded down 4.4% during trading on Tuesday following insider selling activity. The company traded as low as $12.10 and last traded at $12.10. 38,531 shares traded hands during trading, a decline of 49% from the average session volume of 75,509 shares. The stock had previously closed at $12.66.

Specifically, President Songjiang Ma sold 2,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the transaction, the president now directly owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Gyre Therapeutics Stock Down 4.4 %

The stock’s fifty day simple moving average is $12.64 and its 200 day simple moving average is $12.67.

Hedge Funds Weigh In On Gyre Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics in the 2nd quarter worth approximately $218,000. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the second quarter valued at approximately $123,000. WINTON GROUP Ltd purchased a new position in Gyre Therapeutics during the 2nd quarter worth approximately $220,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the second quarter valued at $166,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Gyre Therapeutics by 392.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company’s stock worth $1,425,000 after buying an additional 90,557 shares during the last quarter. 23.99% of the stock is owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.